Mylan, Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Life Sciences will make remdesivir for distribution in countries that “face significant obstacles to healthcare access,” Gilead said.
The deal will be royalty-free until the World Health Organization says COVID-19 is no longer a global health crisis or another pharmaceutical product besides remdesivir or a vaccine is approved to treat or prevent COVID-19.
Remdesivir was granted emergency use authorization by the FDA May 1 after it was shown to shorten the recovery time of some COVID-19 patients in preliminary studies.
Read the full news release here.
More articles on pharmacy:
HHS unveils plan to distribute Gilead’s COVID-19 drug
Two-thirds of hospital pharmacies have reduced staff during COVID-19 pandemic, ASHP survey finds
New CMS rule could raise out-of-pocket drug costs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.